1. Scrip
  2. >>Business
  3. >>Earnings

Vertex Outlines Next Development Steps For Suzetrigine In Pain

 
• By Jessica Merrill

The company has accelerated a Phase II trial testing the NaV1.8 inhibitor in lumbosacral radiculopathy, and a Phase III trial in diabetic peripheral neuropathy will start this quarter.

Vertex updated investors on its diversification strategy • Source: Shutterstock

Vertex Pharmaceuticals Incorporated is already awaiting US Food and Drug Administration approval for its NaV1.8 inhibitor suzetrigine for the treatment of moderate-to-severe acute pain, but the company is advancing the drug into other late-stage clinical trials, with an eye toward expansion in peripheral neuropathic pain.

Key Takeaways
  • Vertex updated investors on Phase III development plans for the NaV1.8 inhibitor suzetrigine and povetacicept for IgA nephropathy (IgAN)

The company updated investors on the development of suzetrigine and other next-generation NaV1.8 and NaV1

More from Earnings

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

More from Business

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.